Mednax Company Profile (NYSE:MD)

About Mednax (NYSE:MD)

Mednax logoMEDNAX, Inc. is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company's national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. As of December 31, 2016, the Company had over 1,390 affiliated physicians providing anesthesia care to patients in connection with surgical and other procedures, as well as pain management. As of December 31, 2016, the Company had 270 affiliated physicians providing maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Healthcare Facilities & Services
  • Sub-Industry: Health Care Services
  • Symbol: NYSE:MD
  • CUSIP: 58502B10
  • Web:
  • Market Cap: $3.92055 billion
  • Outstanding Shares: 92,180,000
Average Prices:
  • 50 Day Moving Avg: $42.95
  • 200 Day Moving Avg: $52.44
  • 52 Week Range: $40.78 - $72.13
  • Trailing P/E Ratio: 13.41
  • Foreward P/E Ratio: 12.69
  • P/E Growth: 0.88
Sales & Book Value:
  • Annual Revenue: $3.34 billion
  • Price / Sales: 1.16
  • Book Value: $30.79 per share
  • Price / Book: 1.37
  • EBITDA: $628.4 million
  • Net Margins: 8.78%
  • Return on Equity: 11.89%
  • Return on Assets: 6.10%
  • Debt-to-Equity Ratio: 0.62%
  • Current Ratio: 1.59%
  • Quick Ratio: 1.59%
  • Average Volume: 1.25 million shs.
  • Beta: 0.37
  • Short Ratio: 8.38

Frequently Asked Questions for Mednax (NYSE:MD)

What is Mednax's stock symbol?

Mednax trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

How were Mednax's earnings last quarter?

Mednax, Inc (NYSE:MD) announced its quarterly earnings data on Friday, July, 28th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.04. The business had revenue of $843 million for the quarter, compared to the consensus estimate of $849.49 million. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The company's quarterly revenue was up 9.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.03 earnings per share. View Mednax's Earnings History.

When will Mednax make its next earnings announcement?

Mednax is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Mednax.

What guidance has Mednax issued on next quarter's earnings?

Mednax updated its third quarter earnings guidance on Friday, July, 28th. The company provided earnings per share (EPS) guidance of $0.83-0.88 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.98.

Where is Mednax's stock going? Where will Mednax's stock price be in 2017?

11 equities research analysts have issued 1 year target prices for Mednax's shares. Their predictions range from $46.00 to $69.00. On average, they anticipate Mednax's stock price to reach $55.44 in the next year. View Analyst Ratings for Mednax.

What are analysts saying about Mednax stock?

Here are some recent quotes from research analysts about Mednax stock:

  • 1. According to Zacks Investment Research, "Mednax, Inc., formerly Pediatrix Medical Group, Inc. is a healthcare services company that focuses on physician services for newborn, maternal-fetal, pediatric subspecialty and anesthesia care. The company ,through its subsidiaries, provides these services in the United States and Puerto Rico. In addition, MEDNAX engages in clinical research, monitoring clinical outcomes, and implementing clinical initiatives. " (10/11/2017)
  • 2. Jefferies Group LLC analysts commented, "Following MD's 5% EPS miss in Q4, we believe our Hold thesis from our December downgrade still holds and would expect the stock to give up some of its premium valuation pending improved earnings visibility. Broader birth trends remain subdued, MD faces its toughest comp of the year in Q1-17, and the company's deal flow remains relatively moderate, leading us to believe that the achievability of Q1 guidance (following 3 consecutive EPS misses) remains uncertain." (2/8/2017)

Who are some of Mednax's key competitors?

Who are Mednax's key executives?

Mednax's management team includes the folowing people:

  • Cesar L. Alvarez, Chairman of the Board
  • Joseph M. Calabro, President, Chief Operating Officer
  • Roger J. Medel M.D., Chief Executive Officer, Director
  • Vivian Lopez-Blanco, Chief Financial Officer, Treasurer
  • David A. Clark, President - MEDNAX National Medical Group Division
  • John C. Pepia, Senior Vice President, Chief Accounting Officer
  • Dominic J. Andreano, Senior Vice President, General Counsel, Secretary
  • Manuel Kadre, Lead Independent Director
  • Karey D. Barker, Independent Director
  • Waldemar A. Carlo M.D., Independent Director

Who owns Mednax stock?

Mednax's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Tandem Investment Advisors Inc. (0.02%). Company insiders that own Mednax stock include Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Karl B Wagner, Manuel Kadre, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Michael D Stanley, Paul G Gabos and Vivian Lopez-Blanco. View Institutional Ownership Trends for Mednax.

Who sold Mednax stock? Who is selling Mednax stock?

Mednax's stock was sold by a variety of institutional investors in the last quarter, including Tandem Investment Advisors Inc.. Company insiders that have sold Mednax stock in the last year include Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Paul G Gabos and Vivian Lopez-Blanco. View Insider Buying and Selling for Mednax.

How do I buy Mednax stock?

Shares of Mednax can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mednax's stock price today?

One share of Mednax stock can currently be purchased for approximately $42.12.

MarketBeat Community Rating for Mednax (NYSE MD)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  229 (Vote Outperform)
Underperform Votes:  270 (Vote Underperform)
Total Votes:  499
MarketBeat's community ratings are surveys of what our community members think about Mednax and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Mednax (NYSE:MD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.09)
Consensus Price Target: $55.44 (31.63% upside)
Consensus Price Target History for Mednax (NYSE:MD)
Price Target History for Mednax (NYSE:MD)
Analysts' Ratings History for Mednax (NYSE:MD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017BMO Capital MarketsInitiated CoverageMarket Perform$46.00N/AView Rating Details
10/3/2017Jefferies Group LLCReiterated RatingHold$46.00MediumView Rating Details
9/17/2017KeyCorpUpgradeSector Weight -> Overweight$51.00LowView Rating Details
9/3/2017Robert W. BairdReiterated RatingHold$47.00MediumView Rating Details
8/1/2017MizuhoReiterated RatingNeutral$62.00 -> $48.00MediumView Rating Details
6/22/2017StephensUpgradeEqual Weight -> Overweight$55.00 -> $68.00HighView Rating Details
5/25/2017Stifel NicolausLower Price TargetHold$65.00 -> $58.00LowView Rating Details
5/4/2017Bank of America CorporationDowngradeBuy -> UnderperformLowView Rating Details
3/10/2017J P Morgan Chase & CoReiterated RatingOverweight -> Neutral$69.00LowView Rating Details
12/9/2016Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$66.00N/AView Rating Details
10/27/2016Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
8/17/2016Citigroup Inc.Lower Price TargetNeutral$76.00 -> $72.00N/AView Rating Details
3/14/2016Piper Jaffray CompaniesReiterated RatingOverweight$76.00N/AView Rating Details
3/7/2016Susquehanna Bancshares IncDowngradePositive -> Neutral$94.00 -> $70.00N/AView Rating Details
(Data available from 10/19/2015 forward)


Earnings History for Mednax (NYSE:MD)
Earnings by Quarter for Mednax (NYSE:MD)
Earnings History by Quarter for Mednax (NYSE MD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$0.87N/AView Earnings Details
7/28/2017Q2 2017$0.81$0.85$849.49 million$843.00 millionViewN/AView Earnings Details
5/4/2017Q1 2017$0.74$0.75$837.01 million$835.60 millionViewN/AView Earnings Details
2/7/2017Q416$1.06$1.00$842.15 million$831.00 millionViewListenView Earnings Details
10/27/2016Q316$1.05$1.09$821.18 million$828.00 millionViewListenView Earnings Details
7/28/2016Q216$1.07$1.03$775.68 million$772.00 millionViewListenView Earnings Details
4/28/2016Q116$0.86$0.87$741.49 million$752.60 millionViewListenView Earnings Details
2/4/2016Q415$1.10$1.13$748.02 million$742.00 millionViewListenView Earnings Details
10/29/2015Q315$0.97$1.10$730.63 million$722.30 millionViewListenView Earnings Details
7/30/2015Q215$0.88$0.97$677.02 million$676.60 millionViewListenView Earnings Details
4/30/2015Q115$0.71$0.72$641.24 million$639.40 millionViewListenView Earnings Details
1/29/2015Q414$0.87$0.89$637.90 million$651.00 millionViewListenView Earnings Details
10/30/2014Q314$0.85$0.86$619.61 million$627.00 millionViewListenView Earnings Details
7/31/2014Q214$0.78$0.79$603.00 million$595.54 millionViewListenView Earnings Details
5/1/2014Q114$0.63$0.63$574.80 million$566.00 millionViewListenView Earnings Details
1/30/2014Q4$0.75$0.20$555.30 million$567.00 millionViewListenView Earnings Details
10/31/2013Q313$1.48$1.52$556.63 million$555.00 millionViewListenView Earnings Details
7/30/2013Q2 2013$1.36$1.37$533.39 million$529.18 millionViewListenView Earnings Details
5/2/2013Q1 2013$1.09$1.10$504.24 million$502.70 millionViewListenView Earnings Details
1/31/2013Q4 2012$1.30$1.32$473.70 million$471.30 millionViewListenView Earnings Details
11/1/2012Q312$1.28$1.32$470.60 million$473.10 millionViewN/AView Earnings Details
7/31/2012$1.19$1.22ViewN/AView Earnings Details
5/3/2012$1.00$0.98ViewN/AView Earnings Details
2/2/2012$1.19$1.19ViewN/AView Earnings Details
11/1/2011$1.18$1.19ViewN/AView Earnings Details
8/2/2011$1.15$1.15ViewN/AView Earnings Details
5/3/2011$0.91$0.94ViewN/AView Earnings Details
2/3/2011$1.12$1.12ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Mednax (NYSE:MD)
2017 EPS Consensus Estimate: $3.58
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.80$0.81$0.81
Q2 20172$0.99$1.00$1.00
Q3 20173$0.77$1.07$0.88
Q4 20173$0.79$1.09$0.90
(Data provided by Zacks Investment Research)


Dividend History for Mednax (NYSE:MD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Mednax (NYSE:MD)
Insider Ownership Percentage: 2.40%
Insider Trades by Quarter for Mednax (NYSE:MD)
Institutional Ownership by Quarter for Mednax (NYSE:MD)
Insider Trades by Quarter for Mednax (NYSE:MD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/12/2017John C PepiaInsiderSell3,000$42.85$128,550.00View SEC Filing  
6/14/2017Md Pascal J GoldschmidtDirectorSell1,969$57.57$113,355.33View SEC Filing  
6/1/2017Joseph M CalabroInsiderSell23,327$55.00$1,282,985.00View SEC Filing  
5/5/2017Manuel KadreDirectorBuy21,704$55.79$1,210,866.16View SEC Filing  
5/5/2017Vivian Lopez-BlancoCFOSell7,778$55.82$434,167.96View SEC Filing  
2/23/2017Enrique SosaDirectorSell10,668$69.65$743,026.20View SEC Filing  
2/17/2017Vivian Lopez-BlancoCFOSell15,164$70.01$1,061,631.64View SEC Filing  
2/16/2017Dominic J AndreanoSVPSell6,000$69.59$417,540.00View SEC Filing  
2/16/2017John C PepiaInsiderSell2,500$69.58$173,950.00View SEC Filing  
2/16/2017Paul G GabosDirectorSell21,336$69.63$1,485,625.68View SEC Filing  
2/10/2017Md Pascal J GoldschmidtDirectorSell25,294$67.82$1,715,439.08View SEC Filing  
2/9/2017Md Carlo A WaldemarDirectorSell5,334$67.90$362,178.60View SEC Filing  
1/17/2017Vivian Lopez-BlancoCFOSell10,000$70.95$709,500.00View SEC Filing  
12/7/2016Md Pascal J GoldschmidtDirectorBuy2,100$66.52$139,692.00View SEC Filing  
9/14/2016Md Pascal J GoldschmidtDirectorSell1,500$65.01$97,515.00View SEC Filing  
6/13/2016Dominic J AndreanoSVPSell3,922$68.80$269,833.60View SEC Filing  
6/8/2016Md Carlo A WaldemarDirectorSell5,334$70.50$376,047.00View SEC Filing  
6/7/2016Karl B WagnerInsiderSell27,482$68.45$1,881,142.90View SEC Filing  
6/1/2016Joseph M CalabroCOOSell28,347$67.78$1,921,359.66View SEC Filing  
6/1/2016Michael D StanleyInsiderSell14,778$67.78$1,001,652.84View SEC Filing  
5/16/2016Dominic J AndreanoSVPSell3,000$68.53$205,590.00View SEC Filing  
5/2/2016Vivian Lopez-BlancoCFOSell9,350$71.22$665,907.00View SEC Filing  
3/11/2016Md Pascal J GoldschmidtDirectorSell3,100$65.00$201,500.00View SEC Filing  
2/29/2016Paul G GabosDirectorSell10,668$67.15$716,356.20View SEC Filing  
12/11/2015Md Pascal J. GoldschmidtDirectorSell5,250$70.99$372,697.50View SEC Filing  
9/8/2015Cesar L. AlvarezDirectorSell10,668$81.00$864,108.00View SEC Filing  
8/27/2015Roger Md MedelCEOSell100,000$80.27$8,027,000.00View SEC Filing  
6/8/2015Karl B WagnerInsiderSell37,820$70.28$2,657,989.60View SEC Filing  
6/3/2015Joseph M CalabroCOOSell108,071$70.51$7,620,086.21View SEC Filing  
3/9/2015Md Pascal J GoldschmidtDirectorSell8,500$71.25$605,625.00View SEC Filing  
2/26/2015Roger Md MedelCEOSell100,000$71.61$7,161,000.00View SEC Filing  
2/20/2015Md Carlo A WaldemarDirectorSell10,668$71.50$762,762.00View SEC Filing  
2/6/2015Dominic J AndreanoSVPSell3,200$70.75$226,400.00View SEC Filing  
2/6/2015Vivian Lopez-BlancoCFOSell8,250$69.95$577,087.50View SEC Filing  
2/2/2015Paul G GabosDirectorSell17,584$68.07$1,196,942.88View SEC Filing  
1/30/2015William C HawkCOOSell3,598$68.50$246,463.00View SEC Filing  
11/14/2014Roger Md MedelCEOSell51,290$62.59$3,210,241.10View SEC Filing  
11/13/2014Roger Md MedelCEOSell63,440$62.55$3,968,172.00View SEC Filing  
11/7/2014Roger Md MedelCEOSell128,833$62.60$8,064,945.80View SEC Filing  
11/5/2014Roger Md MedelCEOSell169,845$62.60$10,632,297.00View SEC Filing  
11/4/2014Roger Md MedelCEOSell15,052$62.52$941,051.04View SEC Filing  
11/3/2014Roger Md MedelCEOSell10,881$62.52$680,280.12View SEC Filing  
10/31/2014Roger Md MedelCEOSell61,592$62.58$3,854,427.36View SEC Filing  
10/30/2014Karl B WagnerInsiderSell40,000$62.50$2,500,000.00View SEC Filing  
10/30/2014Vivian Lopez-BlancoCFOSell8,800$60.00$528,000.00View SEC Filing  
7/30/2014Karl B WagnerInsiderSell80,000$60.00$4,800,000.00View SEC Filing  
6/10/2014Dominic J AndreanoSVPSell2,252$58.48$131,696.96View SEC Filing  
6/6/2014Karl B WagnerInsiderSell44,596$58.53$2,610,203.88View SEC Filing  
6/5/2014William C HawkCOOSell6,911$57.66$398,488.26View SEC Filing  
6/2/2014David A ClarkCOOSell16,230$57.00$925,110.00View SEC Filing  
6/2/2014Michael D StanleyInsiderSell18,006$57.00$1,026,342.00View SEC Filing  
5/9/2014Karl WagnerInsiderSell79,524$57.09$4,540,025.16View SEC Filing  
5/9/2014Md Pascal GoldschmidtDirectorSell30,000$57.11$1,713,300.00View SEC Filing  
5/8/2014Joseph CalabroCOOSell137,500$57.06$7,845,750.00View SEC Filing  
2/20/2014Dominic AndreanoSVPSell3,000$61.00$183,000.00View SEC Filing  
2/10/2014Joseph CalabroCOOSell150,000$55.55$8,332,500.00View SEC Filing  
2/10/2014Md Carlo WaldemarDirectorSell10,668$55.40$591,007.20View SEC Filing  
11/7/2013Enrique SosaDirectorSell5,334$107.00$570,738.00View SEC Filing  
11/7/2013Karl WagnerInsiderSell1,800$107.60$193,680.00View SEC Filing  
9/11/2013William C HawkCOOSell3,162$100.62$318,160.44View SEC Filing  
9/10/2013Dominic J AndreanoSVPSell3,718$99.63$370,424.34View SEC Filing  
8/7/2013Karl WagnerInsiderSell25,000$98.01$2,450,250.00View SEC Filing  
8/2/2013Joseph M CalabroCOOSell36,154$98.57$3,563,699.78View SEC Filing  
6/3/2013David A ClarkCOOSell8,645$91.01$786,781.45View SEC Filing  
6/3/2013Michael D StanleyInsiderSell8,906$91.01$810,535.06View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Mednax (NYSE:MD)
Latest Headlines for Mednax (NYSE:MD)
DateHeadline logoMEDNAX Announces Acquisition of Leading Texas Radiology Practice - October 18 at 6:51 AM logoMednax, Inc (MD) to Release Quarterly Earnings on Wednesday - October 18 at 5:38 AM logoBMO Capital Markets Initiates Coverage on Mednax, Inc (MD) - October 16 at 6:46 PM logoMEDNAX 2017 Third Quarter Conference Call/Webcast Scheduled for Wednesday, November 1, 2017 - October 14 at 2:49 AM logoResearch Analysts Issue Forecasts for Mednax, Inc's Q3 2017 Earnings (MD) - October 11 at 6:32 AM logoMEDNAX Addresses National Opioid Use and Abuse - October 10 at 8:09 PM logoMEDNAX, Inc. – Value Analysis (NYSE:MD) : October 6, 2017 - October 7 at 5:04 AM logoMEDNAX, Inc. breached its 50 day moving average in a Bearish Manner : MD-US : October 5, 2017 - October 6 at 10:18 AM logoMednax, Inc (MD) Expected to Post Quarterly Sales of $867.78 Million - October 4 at 2:54 AM logoMednax, Inc (MD) Rating Reiterated by Jefferies Group LLC - October 3 at 5:20 PM logoMEDNAX Announces Acquisition of Pediatric Urology Practice in South Florida - October 2 at 11:59 AM logoMednax, Inc (MD) Given Consensus Recommendation of "Hold" by Brokerages - September 30 at 2:42 PM logoComparing Mednax (MD) and Concord Medical Services Holdings Limited (CCM) - September 30 at 2:42 PM logoMednax Suffers From Low Patient Admissions, High Expenses - September 29 at 1:41 PM logoMEDNAX Announces Acquisition of Leading Connecticut Radiology Practice - Business Wire (press release) - September 28 at 6:44 PM logoFinancial Contrast: Nobilis Health Corp (HLTH) versus Mednax (MD) - September 28 at 6:24 AM logoMednax (MD) vs. China Cord Blood Corporation (CO) Financial Comparison - September 23 at 2:33 PM logoMednax (MD) vs. Laboratory Corporation of America Holdings (LH) Critical Contrast - September 21 at 6:26 AM logoMednax Stock Down 35% Year to Date: Will It Fall Further? - September 20 at 6:11 AM logoBrokers Offer Predictions for Mednax, Inc's Q3 2017 Earnings (MD) - September 19 at 7:30 AM logoMednax, Inc (MD) Upgraded to Overweight at KeyCorp - September 17 at 9:34 PM logoStocks That Fell to Three-Year Lows in the Week of Sept. 15 - September 17 at 7:40 PM logoMednax, Inc (MD) Insider John C. Pepia Sells 3,000 Shares - September 13 at 8:50 PM logoMEDNAX (MD) Presents At Baird's 2017 Global Healthcare Conference - Slideshow - September 8 at 3:28 AM logoMednax, Inc (MD) Receives Average Rating of "Hold" from Brokerages - September 5 at 2:40 PM logoMednax's (MD) Hold Rating Reaffirmed at Robert W. Baird - September 3 at 1:26 PM logoMednax Becomes Oversold (MD) - August 31 at 7:10 AM logoMEDNAX to Present at the Baird 2017 Global Healthcare Conference - August 30 at 6:26 AM logoPro-Trader Daily: Featured Company News - MEDNAX Acquires Leading South Florida Radiology Practice - August 25 at 8:18 AM logoFeatured Company News - MEDNAX Acquires Leading South Florida Radiology Practice - August 25 at 8:18 AM logoMEDNAX Announces Acquisition of Leading South Florida Radiology Practice - August 24 at 9:06 AM logoMednax buys Miami practice with over 70 physicians - August 24 at 9:06 AM logoSee what the IHS Markit Score report has to say about MEDNAX Inc. - August 16 at 6:05 AM logoETFs with exposure to MEDNAX, Inc. : August 14, 2017 - August 15 at 1:24 AM logoMednax, Inc (NYSE:MD) Receives Consensus Recommendation of "Hold" from Analysts - August 11 at 3:08 PM logoHead to Head Comparison: Universal Health Services (UHS) & Mednax (NYSE:MD) - August 5 at 7:14 AM logoMednax, Inc (MD) Receives Neutral Rating from Mizuho - August 1 at 11:08 AM logoMEDNAX, Inc. :MD-US: Earnings Analysis: Q2, 2017 By the Numbers : July 31, 2017 - July 31 at 8:07 PM logoMEDNAX (MD) Q2 2017 Results - Earnings Call Transcript - July 29 at 7:46 PM logoMEDNAX Reports Second Quarter GAAP EPS of $0.69 - July 29 at 4:28 AM logoEdited Transcript of MD earnings conference call or presentation 28-Jul-17 2:00pm GMT - July 29 at 4:28 AM logoMednax misses Street 2Q forecasts - July 29 at 4:28 AM logoMednax, Inc (NYSE:MD) Issues Quarterly Earnings Results - July 28 at 6:38 PM logoWhy Mednax Tumbled 12% Today Despite Higher Sales - July 28 at 12:50 PM logoMednax, Inc (MD) Releases Q3 Earnings Guidance - July 28 at 10:23 AM logoCritical Contrast: Mednax (MD) vs. TeamHealth Holdings (TMH) - July 25 at 11:02 AM logoETFs with exposure to MEDNAX, Inc. : July 24, 2017 - July 24 at 6:28 PM logo$851.11 Million in Sales Expected for Mednax, Inc (NYSE:MD) This Quarter - July 21 at 7:35 PM logoMEDNAX, Inc. breached its 50 day moving average in a Bearish Manner : MD-US : July 20, 2017 - July 21 at 2:10 AM logoMEDNAX 2017 Second Quarter Conference Call/Webcast Scheduled for Friday, July 28, 2017 - July 18 at 11:14 PM



Mednax (MD) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.